Trexquant Investment LP Phathom Pharmaceuticals, Inc. Transaction History

Trexquant Investment LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$10.26 - $15.7 $415,776 - $636,226	40,524 Added 221.43%	58,825 $610,000
Q2 2023 Aug 11, 2023	BUY	$7.28 - $14.32 $133,231 - $262,070	18,301 New	18,301 $262,000
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $118,786 - $222,678	-18,388 Reduced 55.15%	14,955 $166,000
Q2 2022 Aug 11, 2022	BUY	$6.2 - $15.5 $206,726 - $516,816	33,343 New	33,343 $281,000
Q1 2021 May 13, 2021	SELL	$33.86 - $48.68 $212,031 - $304,834	-6,262 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$33.22 - $50.26 $208,023 - $314,728	6,262 New	6,262 $208,000

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $272M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.